Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamal Mubarak

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Respiratory Medicine|December 17, 2009
Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertensionAdriano R Tonelli, Hassan Alnuaimat, Kamal Mubarak
American Journal of Therapeutics|June 7, 2011
Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogsEric S Papierniak, David T Lowenthal, Kamal Mubarak
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 15, 2010
Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survivalAdriano R Tonelli, Sebastian Fernandez-Bussy, Saba Lodhi, et al.
Arthritis and Rheumatism|February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Respiratory Medicine|December 17, 2009
Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertensionAdriano R Tonelli, Hassan Alnuaimat, Kamal Mubarak
American Journal of Therapeutics|June 7, 2011
Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogsEric S Papierniak, David T Lowenthal, Kamal Mubarak
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 15, 2010
Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survivalAdriano R Tonelli, Sebastian Fernandez-Bussy, Saba Lodhi, et al.
Arthritis and Rheumatism|February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Pageof 1